TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00367094
Drug: Benazepril plus hydrochlorothiazide
Normalized name: benazepril / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02769247
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral naproxen vs placebo
Study: NCT02769247
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: either normal saline or empty oral capsule
Study: NCT03874897
Drug: CAR-CLDN18.2 T-Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2
Study: NCT03626662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume to match experimental drug.
Study: NCT00707304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, twice per day
Study: NCT02714842
Drug: Radiolabelled Diclofenac Tablet A
Normalized name: diclofenac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed release diclofenac sodium tablet (50 mg)
Study: NCT02714842
Drug: Radiolabelled Diclofenac tablet B
Normalized name: diclofenac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed release diclofenac sodium tablet (50 mg)
Study: NCT02714842
Drug: Radiolabelled Diclofenac tablet C
Normalized name: diclofenac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed release diclofenac sodium tablet (25 mg)
Study: NCT02714842
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enteric coated delayed release diclofenac sodium tablet (50 mg)
Study: NCT03874897
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line systemic therapy according to physician's choice
Study: NCT03965117
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is \> 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
Study: NCT00005839
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01978301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
Study: NCT02844075
Drug: MK-3475(pembrolizumab)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery.
Study: NCT01381887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
Study: NCT01630083
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
Study: NCT02142829
Drug: On-Q Pain Ball
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine HCl 0.25%
Study: NCT02414841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04497155
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
Study: NCT02006290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, matching placebo, QD
Study: NCT04665284
Drug: Usual care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
Study: NCT00224419
Drug: CBT + NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
Study: NCT02084446
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
Study: NCT01242215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01242215
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03151603
Drug: Placebo to Arctuvan
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of Placebo to Arctuvan
Study: NCT00561821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet daily
Study: NCT02084446
Drug: Sodium Mycophenolate
Normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
Study: NCT02853084
Drug: HL2351
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be adjusted based on disease activities
Study: NCT00385489
Drug: LXR-623
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00419471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
Study: NCT00667043
Drug: remifentanil and propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
Study: NCT00667043
Drug: fentanyl and midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
Study: NCT02360956
Drug: Antihypertensive medication (per doctor suggestion)
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
Study: NCT00047840
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00047840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04115293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous (SC) injection
Study: NCT02282670
Drug: Stillen tab.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00549523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 0 mg bid (placebo)
Study: NCT00549523
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 400 mg bid of L. frutescens.
Study: NCT04245865
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2800 mg/m2 iv
Study: NCT04245865
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2 orally daily for two weeks
Study: NCT00549523
Drug: Mid Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 800 mg bid of L. frutescens.
Study: NCT00549523
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 1200 mg bid of L. frutescens.
Study: NCT01303887
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
Study: NCT01303887
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
Study: NCT02762890
Drug: Deep neuromuscular blockade
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
Study: NCT02762890
Drug: Moderate neuromuscular blockade
Normalized name: Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
Study: NCT01704573
Drug: 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA.
Study: NCT00970333
Drug: [18F]-FEPPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
Study: NCT02135146
Drug: Plasmalyte 3ml/kg/hr group
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
Study: NCT02135146
Drug: Plasmalyte 6ml/kg/hr group
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
Study: NCT03941431
Drug: Jueyin granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jueyin granules p.o. once a day for 8 weeks.
Study: NCT03941431
Drug: Jueyin placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jueyin placebo granules p.o. once a day for 8 weeks.
Study: NCT02982850
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03696186
Drug: Luminal type-1
Normalized name: WHITE SPIRIT TYPE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Study: NCT03696186
Drug: Luminal type-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
Study: NCT01631877
Drug: Enoxaparin with acenocoumarol
Normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
Study: NCT01086540
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed.
Study: NCT03696186
Drug: Neuroendocrine type-1
Normalized name: WHITE SPIRIT TYPE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Study: NCT03696186
Drug: Neuroendocrine type-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Study: NCT00439426
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Study: NCT00226954
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03696186
Drug: Atypical type-1
Normalized name: WHITE SPIRIT TYPE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
Study: NCT03696186
Drug: Atypical type-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
Study: NCT02015650
Drug: Mitomycin-C/ 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
Study: NCT02404376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrevenous administration of Placebo
Study: NCT02571543
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
Study: NCT03211858
Drug: NovoLog/NovoRapid
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
Study: NCT02466997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00276159
Drug: 852A
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
Study: NCT00592280
Drug: Two-Layer Method pancreas preservation system drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
Study: NCT02465814
Drug: Vilaprisan (BAY1002670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 weeks),Vilaprisan (12 weeks)
Study: NCT02465814
Drug: Vilaprisan (BAY1002670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
Study: NCT03464552
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsule 3 hours before procedure
Study: NCT03464552
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule 3 hours before procedure
Study: NCT00203242
Drug: Depacon IV and Depakote ER
Normalized name: valproate Extended Release Oral Tablet [Depakote]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03449147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered orally BID
Study: NCT01901757
Drug: HCP1201, Fasted followed by fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
Study: NCT01901757
Drug: HCP1201, Fed followed by fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
Study: NCT03602495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo Bid orally, continuously.
Study: NCT00803374
Drug: AntiCD137
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study: NCT00803374
Drug: AntiCD137
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study: NCT00803374
Drug: AntiCD137
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study: NCT00803374
Drug: AntiCD137
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study: NCT00803374
Drug: AntiCD137
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study: NCT02926846
Drug: Intravenous vancomycin & gentamicin with adjunctive lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)
Study: NCT02926846
Drug: Intraperitoneal vancomycin & gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)
Study: NCT01246518
Drug: MOB015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
Study: NCT03523585
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
Study: NCT02237950
Drug: 1% SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
Study: NCT02237950
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
Study: NCT02380157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
Study: NCT03111108
Drug: EBR/GZR (50 mg/100 mg) FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
Study: NCT03692026
Drug: Hyaluronic acid and Melatonin Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
Study: NCT00879372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 12.5 mg TID
Study: NCT03149445
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication will be administered for 91 days.
Study: NCT06639152
Drug: oil-based contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.
Study: NCT03654326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching gefapixant tablet taken orally
Study: NCT03654326
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator